Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $146.8 million.

  • Amphastar Pharmaceuticals' Receivables - Net rose 513.7% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year increase of 513.7%. This contributed to the annual value of $136.3 million for FY2024, which is 1857.09% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Receivables - Net stood at $146.8 million, which was up 513.7% from $133.0 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Receivables - Net's 5-year high stood at $146.8 million during Q3 2025, with a 5-year trough of $67.9 million in Q2 2021.
  • In the last 5 years, Amphastar Pharmaceuticals' Receivables - Net had a median value of $104.7 million in 2023 and averaged $106.9 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first crashed by 612.28% in 2022, then skyrocketed by 5433.4% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Receivables - Net (Quarter) stood at $78.8 million in 2021, then grew by 12.69% to $88.8 million in 2022, then rose by 29.43% to $114.9 million in 2023, then rose by 18.57% to $136.3 million in 2024, then increased by 7.72% to $146.8 million in 2025.
  • Its Receivables - Net was $146.8 million in Q3 2025, compared to $133.0 million in Q2 2025 and $144.6 million in Q1 2025.